Helix BioPharma establishes subsidiary in Poland

Published: 29-Aug-2013

To support ongoing clinical oncology research at Polish research institutions


Helix BioPharma, a Canadian biopharmaceutical company focused on developing cancer treatments, has established a Polish subsidiary. Helix Polska will support ongoing clinical oncology research at leading research institutions in Poland.

'Establishing Helix Polska further strengthens Canadian-Polish relationships and scientific collaboration, which commenced in 2005 when Polish investors first became shareholders of Helix,' said Robert Verhagen, Chief Executive of Helix.

'We recognise that our relationship with the various leading Polish institutions is important to our success, and Helix Polska will allow us more effectively to communicate and interact with these groups.'

Aurora, Ontario-based Helix's product development initiatives are focused primarily on its L-DOS47 and Topical Interferon Alpha-2b new drug candidates, which are currently in clinical trials.

See more

You may also like

Manufacturing

Innovation in generics: increased efficiency through peptide API synthesis expertise

Read more
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  3. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  4. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  5. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Innovation in generics: increased efficiency through peptide API synthesis expertise

Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Research & Development

N4 Pharma and SRI to target and treat previously unreachable human cells

The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Finance

Berry Global invests to increase production capacity for healthcare products

Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Manufacturing

For easy transition from glass to plastic accessories - BOLA components with GL threads

The GL thread is the most common thread on lab equipment made of glass. Available from Labtex in the UK, BOLA offers a modular construction system with many different components with GL threads
Distribution

ChargePoint invest in a single-use manufacturing facility to expand product line

The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Subscribe now